Biotechnology

SEED AWARD Moves Matricelf One Step Closer to Creating World’s First 3D Printed Human Heart

Tuesday, November 19, 2019 - 7:19am

When the creative minds that drive Israeli biotechnology company Matricelf started telling people about their plan to create the worlds first 3D printed human heart the common response was that they were talking about the stuff of dreams.

Key Points: 
  • When the creative minds that drive Israeli biotechnology company Matricelf started telling people about their plan to create the worlds first 3D printed human heart the common response was that they were talking about the stuff of dreams.
  • It is a huge challenge to take an idea from the academic world to the real world, said Matricelf CEO, Asaf Toker.
  • As it said it is a seed award and it will help bring our ideas to life.
  • The company itself was established in April 2019 and made headlines earlier this year when it printed the first ever 3D human heart, part of its continued efforts to explore the potential of printed organs and tissues.
Tags: 
Electronic design automation, Health, Technology, Research, Science, Biotechnology, Emerging technologies, Industrial design, Industrial processes, 3D printing, DIY culture, Articles, Organ, Asaf, Design, Technology

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Tuesday, November 19, 2019 - 1:32am

These options were granted under the Pulse Biosciences 2017 Inducement Equity Incentive Plan.

Key Points: 
  • These options were granted under the Pulse Biosciences 2017 Inducement Equity Incentive Plan.
  • The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individuals entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
  • The options are subject to the terms and conditions of the 2017 Inducement Equity Incentive Plan and the award agreements entered into with each recipient.
  • All options are subject to the recipients continued employment with Pulse Biosciences through the respective vesting dates.
Tags: 
Biotechnology, Pharmaceutical, Health, Medical devices, Law, Inheritance, Labour law, Property law, Vesting, Inducement rule, Private law

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Abeona Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ABEO

Tuesday, November 19, 2019 - 1:17am

NEW YORK, Nov. 18, 2019 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO) and certain of its officers.

Key Points: 
  • NEW YORK, Nov. 18, 2019 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Abeona is a clinical-stage biopharmaceutical company that purports to develop cell and gene therapies for life-threatening rare genetic diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.
Tags: 
Life sciences, Articles, Biotechnology, Abraham Pomerantz, Securities Class Action, Biopharmaceutical, Pomerantz, Abeona

The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018-2024

Monday, November 18, 2019 - 8:15pm

The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 20182024.

Key Points: 
  • The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 20182024.
  • The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period:
    The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2018?2024.
  • Cell and Gene Therapy Market: Segmentation
    This research report includes detailed market segmentation by product, application, end-user, and geography.
  • The global cell therapy market is growing at a steady rate, and this trend is expected to continue during the forecast period due to the increased patient base with a wide range of diseases/ailments.
Tags: 
Articles, Branches of biology, Life sciences, Emerging technologies, Genetic engineering, Bioethics, Biotechnology, Market segmentation, Marketing, Therapy, Gene therapy, Image segmentation

Morphic to Present at the Jefferies 2019 London Healthcare Conference

Monday, November 18, 2019 - 9:15pm

WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, todayannounced that Praveen Tipirneni, M.D., president and chief executive officer, is scheduled to present a corporate overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 1:20 p.m. GMT, in London.

Key Points: 
  • WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, todayannounced that Praveen Tipirneni, M.D., president and chief executive officer, is scheduled to present a corporate overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 1:20 p.m. GMT, in London.
  • A live webcast of the presentation will be available on the Investors section of Morphics website at https://www.morphictx.com .
  • An archived replay will be available on the companys website for a period of 90 days after the conference.
  • Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
Tags: 
Life sciences, Articles, Health, Pharmaceutical industry, Specialty drugs, Biopharmaceutical, Biotechnology, Pharmacy, Medication, Autoimmunity

Trevena to Present at the Stifel 2019 Healthcare Conference

Monday, November 18, 2019 - 10:05pm

CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will present at the Stifel 2019 Healthcare Conference, sponsored by Stifel, to be held at the Lotte New York Palace Hotel in New York City on Wednesday, November 20, 2019 at 8:35 a.m. EST.

Key Points: 
  • CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will present at the Stifel 2019 Healthcare Conference, sponsored by Stifel, to be held at the Lotte New York Palace Hotel in New York City on Wednesday, November 20, 2019 at 8:35 a.m. EST.
  • A live audio webcast and archived replay of the presentation will be available on Trevenas investor relations website at https://investors.trevena.com/ .
  • Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders.
Tags: 
Life sciences, Articles, Biotechnology, Trevena, Stifel, Biopharmaceutical

InterVenn Biosciences Announces Positive Interim Clinical Trial Results and Appoints Biotech Veteran Klaus Lindpaintner, M.D. as Chief Scientific and Medical Officer

Monday, November 18, 2019 - 9:53pm

The interim results confirmed that the InterVenn test performance significantly exceeds that of the current state-of-the-art ovarian cancer test, CA 125, with both markedly better specificity and sensitivity.

Key Points: 
  • The interim results confirmed that the InterVenn test performance significantly exceeds that of the current state-of-the-art ovarian cancer test, CA 125, with both markedly better specificity and sensitivity.
  • InterVenn Biosciences also announced the latest addition to its team, Klaus Lindpaintner , MD, MPH, FACP, FACMG, as Chief Scientific Officer and Chief Medical Officer, a role in which he will be the head all of InterVenns global scientific operations and clinical affairs.
  • Previous to that, Klaus served as a faculty member at Harvard Medical School and the Harvard School of Public Health.
  • InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine.
Tags: 
Biotechnology, Technology, Health, Women, Pharmaceutical, Oncology, Research, Software, Consumer, Science, Clinical trials, Academic disciplines, Biomarkers, Sensitivity and specificity, Agilent Technologies, Biology, Companies

Karuna Therapeutics Announces Proposed Public Offering of Common Stock

Monday, November 18, 2019 - 9:21pm

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000 shares of its common stock.

Key Points: 
  • Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000 shares of its common stock.
  • Karuna intends to grant the underwriters a 30-day option to purchase an additional 390,000 shares of its common stock, at the public offering price, less the underwriting discounts and commissions.
  • The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size and terms of the offering.
  • All the shares to be sold in the proposed offering will be sold by Karuna.
Tags: 
Biotechnology, Mental health, Health, Pharmaceutical, Clinical trials, Finance, Money, Financial markets, Corporate finance, Initial public offering, Stock market, Underwriting, Public offering, Stock

Researchers Present New Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2019 Chemical and Biological Defense Science & Technology Conference

Monday, November 18, 2019 - 9:35pm

Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, today announced that Dr. Carl Gelhaus, Senior Program Manager of the Medical Countermeasures Division at MRIGlobal, will present positive interim data on Appilis ATI-1701 program at the Chemical and Biological Defense Science & Technology Conference (CBD S&T).

Key Points: 
  • Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, today announced that Dr. Carl Gelhaus, Senior Program Manager of the Medical Countermeasures Division at MRIGlobal, will present positive interim data on Appilis ATI-1701 program at the Chemical and Biological Defense Science & Technology Conference (CBD S&T).
  • Researchers will conduct an additional evaluation of vaccine efficacy up to 365 days in the same model in H1 2020.
  • The U.S. Defense Threat Reduction Agency (DTRA), an arm of the U.S. Department of Defense (DOD), is funding this trial.
  • Attendees will also network with DTRA science and technology managers as well as other members of DTRAs Chemical and Biological Defense team.
Tags: 
Biotechnology, Pharmaceutical, Health, Weapons of mass destruction, Defense Threat Reduction Agency, Nuclear proliferation, MRIGlobal, Institutes, Organizations, Research

Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference

Monday, November 18, 2019 - 9:05pm

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.
  • Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation.
  • For more information about Sangamo, visit www.sangamo.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005718/en/
Tags: 
Health, Stem cells, Genetics, Research, Science, Biotechnology, Branches of biology, Biology, Life sciences, Genetic engineering, Sangamo Therapeutics, Bioethics, Emerging technologies, Biotechnology, Gene therapy, Genome editing